Njord International AB has signed a commercial distribution agreement with Quadri Pharma LLC to commercialise Njord’s patient transfer solution Atle® 180 in the United Arab Emirates (UAE). This partnership unites Njord Medtech's cutting-edge medical technology with Quadri Pharma's strong relationships and experience in the UAE healthcare market.
Quadri Pharma, have been at the forefront of this industry since their establishment in Egypt in 1994. With a mission to provide professional and reliable technical services and solutions, they expanded to the UAE in 2002, bringing their expertise to meet the growing demands of the regional healthcare market.
“We truly look forward to join forces with Muhyee and the strong team at Quadri Pharma. Their trust based approach and proven track record of introducing new medical devices and workflows are key capabilities to leverage while introducing Atle 180, creating a more resilient acute care operating model” says Jacob Ahrnstein, CEO Njord Medtech
Atle® 180 will be introduced to the UAE market during the autumn of 2025.
For further information, please contact: hello@njordmedtech.com